<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Imiquimod: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Imiquimod: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Imiquimod: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11264" href="/d/html/11264.html" rel="external">see "Imiquimod: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F182270"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aldara [DSC];</li>
<li>Zyclara;</li>
<li>Zyclara Pump</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867188"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aldara P;</li>
<li>TARO-Imiquimod Pump;</li>
<li>Vyloma;</li>
<li>Zyclara</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F182299"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Skin and Mucous Membrane Agent;</li>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F182273"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4bb58f89-580c-47cf-bf9c-e5c96334fe50">Actinic keratosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic keratosis: Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>2.5% and 3.75% cream: </b>Apply thin film (using up to 2 packets or 2 full pump actuations) once daily before bedtime for 2 weeks to the skin of the affected area (either the entire face or balding scalp, but not both concurrently); leave on for ~8 hours, then remove with mild soap and water. After a 2-week period of no treatment, repeat with a second 2-week treatment (do not extend treatment cycles because of missed doses or rest periods). Maximum to be prescribed: 56 packets or 2 x 7.5 g pumps per 2 cycles of treatment. Treatment should continue for the full treatment course even if all actinic keratoses appear to be gone (do not extend the treatment period because of missed doses or rest periods).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>5% cream: </b>Apply 2 times per week (using up to 1 packet per application), prior to normal sleeping hours, to a defined treatment area(s) on the face or scalp (but not both concurrently; treatment should be limited to areas ≤25 cm<sup>2</sup>); leave on for ~8 hours, then remove with mild soap and water. Maximum to be prescribed: 36 packets per 16-week treatment period. Treatment should continue for 16 weeks (do not extend the treatment period beyond 16 weeks because of missed doses or rest periods).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="87966864-94b9-43e8-8609-89f9f255dc09">Basal cell carcinoma, superficial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Basal cell carcinoma, superficial (Aldara 5% cream): </b>
<b>Topical: </b>Apply once daily 5 days per week, prior to normal sleeping hours, for 6 weeks; leave on skin for ~8 hours, then remove with mild soap and water. Apply enough cream to cover the treatment area, including 1 cm of skin surrounding the tumor. Tumor treatment area should not exceed 3 cm (maximum of 2 cm tumor diameter plus a 1 cm margin of skin around the tumor). The diameter of cream droplet applied should range from 4 mm to 7 mm for tumor areas of 0.5 cm to 2 cm, respectively. Maximum to be prescribed: 36 packets during the 6-week treatment period. Safety/efficacy of repeated use in a previously treated area have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-</i>
<i>label dosing (may be better tolerated):</i> Apply once every other day; may include a treatment holiday during weekends or in the middle of a treatment course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29331385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29331385'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad0be644-c83b-44e8-b41f-3c4b3080aa65">Cutaneous flat warts</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous flat warts (off-label use):</b>
<b>Topical (5% cream):</b> Apply once daily at bedtime until warts completely disappear up to a maximum of 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062069'])">Ref</a></span>). Additional data may be necessary to further define the role of imiquimod in this condition.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="36fe1b54-3af2-4107-bfdb-9cca8fc70fc3">Cutaneous squamous cell carcinoma in situ, low-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous squamous cell carcinoma in situ (Bowen disease), low-risk (off-label use): Topical (5% cream):</b> Apply to target lesion once daily for 16 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11209116','lexi-content-ref-16713457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11209116','lexi-content-ref-16713457'])">Ref</a></span>) <b>or </b>apply to target lesion once daily (apply every other day if genital lesion) for at least 6 weeks, and up to 20 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17430376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17430376'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ffac1191-d686-420b-acb0-34312f8995c8">Genital and perianal warts</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Genital and perianal warts: Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>3.75% cream:</b> Apply a thin layer once daily (using up to 1 packet or 1 full actuation of pump) prior to bedtime; leave on skin for ~8 hours, then remove with mild soap and water. Continue treatment until there is total clearance of the warts or for a maximum duration of therapy of 8 weeks. Maximum to be prescribed: 56 packets or 2 x 7.5 g pumps per course of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>5% cream:</b> Apply a thin layer 3 times per week (on alternate days) prior to bedtime; leave on skin for 6 to 10 hours, then remove with mild soap and water. Continue until there is total clearance of the genital/perianal warts or for a maximum duration of therapy of 16 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e206eb06-9845-4cb7-a6df-71009e28a7a8">Herpes simplex virus infection, genital, acyclovir resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus infection, genital, acyclovir resistant (off-label use):</b>
<b>Topical (5% cream):</b> Apply to lesions 3 times per week (leaving on skin for 8 hours per application) until clinical resolution (in patients with HIV, generally ≥21 to 28 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1baf4f7-99b6-4911-a226-700b34355812">Melanoma in situ, lentigo maligna type</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma in situ, lentigo maligna type (off-label use): Topical (5% cream):</b> Apply to lesion (including a margin of 0.5 to 1 cm around the lesion) 5 nights a week for 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18812714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18812714'])">Ref</a></span>) or apply to lesion (including a margin of 2 cm around the lesion) 3 to 5 times a week for 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25791801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25791801'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0100d02f-de55-45e2-ae30-7e27fc8fd6e6">Mycosis fungoides, early stage, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycosis fungoides, early stage, refractory (off-label use): Topical (5% cream):</b> Apply to lesions 3 times a week for 12 weeks; if significant irritation occurs at a lesion site, can decrease the frequency of application to a minimum frequency of once a week; refer to study for dosage adjustment details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15692473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15692473'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5505f67-cebd-4c6a-86a2-49313164e5a2">Penile cancer, superficial/noninvasive disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Penile cancer, superficial/noninvasive disease (off-label use): Topical (5% cream): </b> Apply to lesions every 48 hours (leaving on skin for 12 hours per application) for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22421082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22421082'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991324"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988668"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F46324650"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Local skin reactions (eg, erythema, edema, skin erosion/weeping, scabbing): Temporarily interrupt treatment for up to several days for severe or intolerable reactions; may consider resuming therapy once reaction subsides.</p>
<p style="text-indent:-2em;margin-left:2em;">Systemic/flu-like reactions (eg, malaise, fever, rigors): Consider temporary interruption of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Vulvar swelling: Interrupt or discontinue therapy for severe vulvar swelling.</p></div>
<div class="block doe drugH1Div" id="F182274"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F182288"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ffac1191-d686-420b-acb0-34312f8995c8">Genital and perianal warts</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Genital and perianal warts (3.75% and 5% cream): </b>Children ≥12 years and Adolescents: Topical: Refer to adult dosing.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Local skin reactions (eg, erythema, edema, skin erosion/weeping, scabbing): Temporarily interrupt treatment for up to several days for severe or intolerable reactions; may consider resuming therapy once reaction subsides.</p>
<p style="text-indent:-2em;margin-left:4em;">Systemic/flu-like reactions (eg, malaise, fever, rigors): Consider temporary interruption of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Vulvar swelling: Interrupt or discontinue therapy for severe vulvar swelling.</p></div>
<div class="block dorp drugH1Div" id="F51113734"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51113735"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F182248"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency of reactions vary and are related to the degree of inflammation associated with the treated disease, number of weekly applications, product formulation, and individual sensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Localized erythema (58% to 100%; remote: 2%), xeroderma (local; including flaking, scaling; 18% to 93%; remote: 1%), crusted skin (local; 4% to 93%), skin sclerosis (local; 5% to 84%), dermal ulcer (local; 4% to 62%; remote: 2%), localized vesiculation (2% to 31%), excoriation (local; remote: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (2% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized edema (12% to 78%; remote: 1%), application site discharge (22% to 51%), local pruritus (3% to 32%), localized burning (9% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (15% to 33%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, localized blanching</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (2% to 6%), fatigue (1% to 4%), dizziness (&lt;1% to 3%), local discomfort (soreness; ≤3%), rigors (1%), anxiety, pain, tingling of skin (local)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin pain (local; 1% to 8%), skin hypertrophy (local; 3%), skin infection (local; 1% to 3%), eczema (2%), cheilitis (≤2%), alopecia (1%), dermal hemorrhage (local), localized rash, papule (local), seborrhoeic keratosis, skin tenderness (local), stinging of the skin (local), tinea (cruris)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1% to 4%), diarrhea (1% to 3%), anorexia (≤3%), vomiting (1%), dyspepsia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bacterial vaginosis (3%), urinary tract infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Squamous cell carcinoma (4%), lymphadenopathy (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local irritation (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 3%), myalgia (≥1%), back pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (7%), flu-like symptoms (&lt;1% to 4%), cough, pharyngitis, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Abdominal pain, acute exacerbations of multiple sclerosis, agitation, anemia, angioedema, atrial fibrillation, capillary leak syndrome, cardiac failure, cardiomyopathy, cellulitis (local), cerebrovascular accident, chills, depression, dermatitis, dyspnea, dysuria, erythema multiforme, erythema (scrotal), exacerbation of psoriasis, exacerbation of ulcerative colitis, exfoliative dermatitis, febrile seizures, Henoch-Schönlein purpura (IgA vasculitis), hepatic insufficiency, herpes zoster, hyperpigmentation, immune thrombocytopenia (ITP), insomnia, ischemia, lethargy, leukopenia, malignant lymphoma, myocardial infarction, pain (scrotal), palpitations, pancytopenia, paresis, proteinuria, psoriasis, pulmonary edema, scrotal edema, seizure, squamous cell carcinoma, supraventricular tachycardia, syncope, tachycardia, thrombocytopenia, thyroiditis, ulcerative colitis, ulcer (scrotal), urinary retention, urticaria, vertebral disk disease (spondylitis onset or exacerbated)</p></div>
<div class="block coi drugH1Div" id="F10184536"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to imiquimod or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F182245"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Local inflammatory reactions: Intense local inflammatory reactions (including skin weeping or erosion) may occur after a few applications; may be accompanied by systemic symptoms (fever, malaise, myalgia); reactions may extend beyond the application site. Imiquimod has the potential to exacerbate inflammatory conditions of the skin (including chronic graft-versus-host disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Due to the potential for increased sensitivity to sunlight, avoid or minimize sunlight exposure (including sunlamps or other artificial sunlight exposure) during treatment. Advise patients to wear protective clothing (eg, a hat) during treatment. Patients with sunburn should not to use imiquimod until full recovery form sunburn. Patients with a potential for considerable sun exposure (eg, due to their occupations) or inherent sensitivity to sunlight should use caution during imiquimod treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic reactions: Flu-like symptoms (arthralgias, chills, fatigue, fever, malaise, myalgias, nausea, rigors) may accompany or precede local inflammatory reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vulvar swelling: Severe local inflammation of female external genitalia following topical application may lead to severe vulvar swelling and urinary retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Actinic keratosis: Safety and efficacy have not been established in the treatment of actinic keratosis with repeat use (more than 1 treatment course) in the same area. Safety of imiquimod 5% applied to areas of skin larger than 25 cm<sup>2</sup> has not been established. Lymphadenopathy has occurred in patients being treated for actinic keratosis; lymphadenopathy resolved within 4 weeks after completion of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disorders: Safety and efficacy in immunosuppressed patients have not been established. Use with caution in patients with preexisting autoimmune disorders (onset or exacerbation of disease has been reported).</p>
<p style="text-indent:-2em;margin-left:4em;">• Basal cell carcinoma: Use should be limited to superficial carcinomas with a maximum diameter of 2 cm. Safety and efficacy in treatment of other types of basal cell carcinoma (BCC) lesions of the face, head, and anogenital area, or other subtypes of BCC (including nodular and morpheaform), have not been established. Patients with superficial BCC treated with imiquimod should have regular follow up of the treatment site.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human papilloma viral disease: Imiquimod has not been evaluated for the treatment of urethral, intravaginal, cervical, rectal, or intra-anal human papilloma viral disease and is not recommended for these conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage forms specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not intended for oral, nasal, intravaginal, or ophthalmic use. Administration is not recommended until tissue is healed from any previous drug or surgical treatment. Treatment should not be prolonged beyond recommended period due to missed doses or rest periods. Safety and efficacy have not been established for basal cell nevus syndrome, in immunocompromised patients, or for xeroderma pigmentosum. Safety and efficacy of the 2.5% cream in the treatment of external genital warts have not been established.</p></div>
<div class="block foc drugH1Div" id="F182256"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aldara: 5% (12 ea [DSC]) [contains benzyl alcohol, cetyl alcohol, methylparaben, propylparaben, sorbitan monostearate(sorbitan stearate)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zyclara: 3.75% (28 ea) [contains benzyl alcohol, cetyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zyclara Pump: 2.5% (7.5 g); 3.75% (7.5 g) [contains benzyl alcohol, cetyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3.75% (28 ea, 7.5 g); 5% (1 ea, 12 ea, 24 ea)</p></div>
<div class="block geq drugH1Div" id="F182241"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F182263"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Imiquimod External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.75% (per each): $46.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $2.50 - $36.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Zyclara External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.75% (per each): $52.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Zyclara Pump External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5% (per gram): $197.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.75% (per gram): $197.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867189"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aldara P: 5% (1 ea) [contains benzyl alcohol, cetyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyloma: 3.75% (4 ea, 7.5 g, 15 g, 28 ea) [contains benzyl alcohol, cetyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zyclara: 3.75% (7.5 g, 12 ea, 28 ea) [contains benzyl alcohol, cetyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5% (7.5 g)</p></div>
<div class="block adm drugH1Div" id="F182258"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> Wash hands prior to and following application. For topical use only; not for ophthalmic, oral, intra-anal, or intravaginal use. Avoid use in or on the lips and nostrils; do not use in or near the eyes. Do not occlude the application site. Pump (Zyclara) should be primed prior to first use only by pressing top of pump completely down repeatedly until cream appears; discard cream obtained during priming; no further priming is required throughout therapy. If indicated, remove cream by washing the area with mild soap and water.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Actinic keratosis:</i> The treatment area should be washed with mild soap and thoroughly dried (~10 minutes) prior to application. Apply 5% cream over a single contiguous area (~25 cm<sup>2</sup>) on the face or scalp or 2.5% and 3.75% cream over an area on the face or scalp. Both face and scalp should not be treated concurrently. Apply a thin layer to the affected area and rub in until the cream is no longer visible. A transient increase in actinic keratosis lesion counts may be observed during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Basal cell carcinoma, superficial (Aldara):</i> Treatment area should have a maximum diameter no more than 2 cm on the trunk, neck, or extremities (excluding the hands, feet, and anogenital skin). Treatment area should include a 1 cm margin around the tumor. Wash and thoroughly dry treatment area prior to application; apply a thin layer to the affected area (and margin) and rub in until the cream is no longer visible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Genital/perianal warts:</i> Apply a thin layer to external or perianal wart area and rub in until the cream is no longer visible. Avoid use of excessive amounts of cream. Nonocclusive dressings (such as cotton gauze or cotton underwear) may be used in the management of skin reactions.</p></div>
<div class="block admp drugH1Div" id="F52613042"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: Wash hands prior to and following application. For topical use only; not for ophthalmic, oral, intra-anal, or intravaginal use. Avoid use in or on the lips and nostrils; do not use in or near the eyes. Do not occlude the application site. Pump (Zyclara) should be primed prior to first use by pressing top of pump completely down repeatedly until cream appears; discard cream obtained during priming; no further priming is required throughout therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Genital/perianal warts:</i> Apply a thin layer to external or perianal wart area and rub in until the cream is no longer visible. Avoid use of excessive amounts of cream. Apply at bedtime and leave on for 6 to 10 hours, then remove with soap and water. Nonocclusive dressings (such as cotton gauze or cotton underwear) may be used in the management of skin reactions.</p></div>
<div class="block use drugH1Div" id="F182257"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic keratosis (2.5%, 3.75% and 5% cream):</b> Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratoses on the full face or scalp in immunocompetent adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Basal cell carcinoma, superficial (Aldara 5% cream):</b> Topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma in immunocompetent adults with a maximum tumor diameter of 2 cm located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Genital and perianal warts (3.75% and 5% cream):</b> Treatment of external genital and perianal warts (condyloma acuminata) in patients 12 years and older.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Safety and efficacy has not been established in immunosuppressed patients and in patients with basal cell nevus syndrome or xeroderma pigmentosum, or for prevention or transmission of HPV. Imiquimod should be used with caution in patients with preexisting autoimmune conditions. Imiquimod has been evaluated in pediatrics ages 2 to 12 with molluscum, contagiosum, however, studies failed to demonstrate efficacy.</p></div>
<div class="block off-label drugH1Div" id="F25726652"><span class="drugH1">Use: Off-Label: Adult</span><p>Cutaneous flat wart; Cutaneous squamous cell carcinoma in situ (Bowen disease), low-risk; Herpes simplex virus infection, genital, acyclovir resistant; Melanoma in situ, lentigo maligna type; Mycosis fungoides, early stage, refractory; Penile cancer, superficial/noninvasive disease</p></div>
<div class="block mst drugH1Div" id="F182306"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aldara may be confused with Alora, Lialda</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F182294"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F182250"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53575788"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Imiquimod may weaken condoms and vaginal diaphragms.</p></div>
<div class="block pri drugH1Div" id="F1630402"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Imiquimod appears to pose a low risk when used topically for anogenital warts but use in pregnant patients should be avoided until additional data are available (CDC [Workowski 2021]).</p></div>
<div class="block brc drugH1Div" id="F16575966"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if imiquimod is present in breast milk. The manufacturer recommends that caution be exercised when administering imiquimod to breastfeeding patients.</p></div>
<div class="block mop drugH1Div" id="F182254"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Assess response to therapy periodically (reduction in lesion size is indicative of a therapeutic response); monitor for local skin reactions and for signs and symptoms of hypersensitivity to imiquimod.</p></div>
<div class="block pha drugH1Div" id="F182244"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Imiquimod, an immune response modifier, is a Toll-like receptor 7 agonist that activates immune cells. Topical application to the skin is associated with increases in markers for cytokines and immune cells.</p></div>
<div class="block phk drugH1Div" id="F182260"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal; systemic absorption more dependent upon surface area of application as opposed to dose</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 9 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;3% of applied dose as imiquimod and metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F182264"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Imimore 3.75 | Miquimod | Modulcass | Quinilan | Virosupril</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Iminod</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aldara</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Modulcass | Modumiq | Tocasol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Aldara | Li ke jie | Lian bang ai de xin | Na bo | Nan bo | Tian rui</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Imik | Kindara | Virosupril</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aldara</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Quimara 1 | Virosupril</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Euquim | Miquimod | Quimara</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aldara</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Imidara</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aldara | Imich</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aldara</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Genimod</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Barlistad | Imiquimod landsteiner | Quimara | Quimara 1</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Modulcass | Virosupril</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zyclara</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Imat | Imipoc | Miquimod | Virosupril</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aldara | G-warts</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aldara | Vartocid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Kozamod</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bascellex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aldara | You Care</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Imicass | Imik | Miquimod | Modulcass | Virosupril</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Virosupril</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Glentriz</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17205432">
<a name="17205432"></a>Abbo L, Vincek V, Dickinson G, Shrestha N, Doblecki S, Haslett PA. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. <i>Clin Infect Dis</i>. 2007;44(3):e25-e27. doi:10.1086/510426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/17205432/pubmed" id="17205432" target="_blank">17205432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valeant.1">
<a name="Valeant.1"></a>Aldara (imiquimod) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valeant.2">
<a name="Valeant.2"></a>Aldara (imiquimod) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; December 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>Aldara P (imiquimod) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22421082">
<a name="22421082"></a>Alnajjar HM, Lam W, Bolgeri M, et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. <i>Eur Urol</i>. 2012;62(5):923-928. doi:10.1016/j.eururo.2012.02.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/22421082/pubmed" id="22421082" target="_blank">22421082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23794286">
<a name="23794286"></a>Bath-Hextall FJ, Matin RN, Wilkinson D, Leonardi-Bee J. Interventions for cutaneous Bowen's disease. <i>Cochrane Database Syst Rev</i>. 2013;2013(6):CD007281. doi:10.1002/14651858.CD007281.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/23794286/pubmed" id="23794286" target="_blank">23794286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29331385">
<a name="29331385"></a>Bichakjian C, Armstrong A, Baum C, et al; Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. <i>J Am Acad Dermatol</i>. 2018;78(3):540-559. doi:10.1016/j.jaad.2017.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/29331385/pubmed" id="29331385" target="_blank">29331385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16421805">
<a name="16421805"></a>Brummitt CF. Imiquimod 5% cream for the treatment of recurrent, acyclovir-resistant genital herpes. <i>Clin Infect Dis</i>. 2006;42(4):575. doi:10.1086/499529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/16421805/pubmed" id="16421805" target="_blank">16421805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15692473">
<a name="15692473"></a>Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. <i>J Am Acad Dermatol</i>. 2005;52(2):275-280. doi:10.1016/j.jaad.2004.04.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/15692473/pubmed" id="15692473" target="_blank">15692473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12196749">
<a name="12196749"></a>Geisse JK, Rich P, Pandya A, et al, “Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma: A Double-Blind, Randomized, Vehicle-Controlled Study,” <i>J Am Acad Dermatol</i>, 2002, 47(3):390-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/12196749/pubmed" id="12196749" target="_blank">12196749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12614409">
<a name="12614409"></a>Goldgeier M, Fox CA, Zavislan JM, et al, “Noninvasive Imaging, Treatment, and Microscopic Confirmation of Clearance of Basal Cell Carcinoma,” <i>Dermatol Surg</i>, 2003, 29(3):205-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/12614409/pubmed" id="12614409" target="_blank">12614409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fougera.1">
<a name="Fougera.1"></a>Imiquimod cream 5% [prescribing information]. Melville, NY: Fougera Pharmaceuticals Inc; July 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33994168">
<a name="33994168"></a>Issa A, Sebro K, Kwok A, et al. Treatment options and outcomes for men with penile intraepithelial neoplasia: a systematic review. <i>Eur Urol Focus</i>. 2022;8(3):829-832. doi:10.1016/j.euf.2021.04.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/33994168/pubmed" id="33994168" target="_blank">33994168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17062069">
<a name="17062069"></a>Kim MB, Ko HC, Jang HS, Oh CK, Kwon KS. Treatment of flat warts with 5% imiquimod cream. <i>J Eur Acad Dermatol Venereol</i>. 2006;20(10):1349-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/17062069/pubmed" id="17062069" target="_blank">17062069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35044047">
<a name="35044047"></a>Kristiansen S, Torbrand C, Svensson Å, et al. Incidence of penile intraepithelial neoplasia and treatment strategies in Sweden 2000-2019. <i>BJU Int</i>. 2022;129(6):752-759. doi:10.1111/bju.15688<b></b>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/35044047/pubmed" id="35044047" target="_blank">35044047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11209116">
<a name="11209116"></a>Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. <i>J Am Acad Dermatol</i>. 2001;44(3):462-470. doi:10.1067/mjd.2001.111335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/11209116/pubmed" id="11209116" target="_blank">11209116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18812714">
<a name="18812714"></a>Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo maligna. <i>Ann Plast Surg</i>. 2008;61(4):419-424. doi:10.1097/SAP.0b013e31816714c8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/18812714/pubmed" id="18812714" target="_blank">18812714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20691883">
<a name="20691883"></a>Minhas S, Manseck A, Watya S, Hegarty PK. Penile cancer--prevention and premalignant conditions. <i>Urology</i>. 2010;76(2 suppl 1):S24-S35. doi:10.1016/j.urology.2010.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/20691883/pubmed" id="20691883" target="_blank">20691883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26088690">
<a name="26088690"></a>Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. <i>J Am Acad Dermatol</i>. 2015;73(2):205-212. doi:10.1016/j.jaad.2015.05.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/26088690/pubmed" id="26088690" target="_blank">26088690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12575864">
<a name="12575864"></a>Oster-Schmidt C, Altmeyer P, and Stucker M, “Successful Treatment of Basal Cell Carcinoma on the Face With Imiquimod 5% Cream,” <i>Acta Derm Venereol</i>, 2002, 82(6):477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/12575864/pubmed" id="12575864" target="_blank">12575864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16713457">
<a name="16713457"></a>Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. <i>J Am Acad Dermatol</i>. 2006;54(6):1025-1032. doi:10.1016/j.jaad.2006.01.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/16713457/pubmed" id="16713457" target="_blank">16713457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21406577">
<a name="21406577"></a>Perkins N, Nisbet M, Thomas M. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. <i>Sex Transm Infect</i>. 2011;87(4):292-295. doi:10.1136/sti.2010.047431<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/21406577/pubmed" id="21406577" target="_blank">21406577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17430376">
<a name="17430376"></a>Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. <i>Dermatol Surg</i>. 2007;33(4):427-431; discussion 431-432. doi:10.1111/j.1524-4725.2007.33089.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/17430376/pubmed" id="17430376" target="_blank">17430376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21767324">
<a name="21767324"></a>Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma in situ: a review. <i>Dermatol Surg</i>. 2011;37(10):1394-1411. doi:10.1111/j.1524-4725.2011.02088.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/21767324/pubmed" id="21767324" target="_blank">21767324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20133013">
<a name="20133013"></a>Swanson N, Abramovits W, Berman B, et al, “Imiquimod 2.5% and 3.75% for the Treatment of Actinic Keratoses: Results of Two Placebo-Controlled Studies of Daily Application to the Face and Balding Scalp for Two 2-Week Cycles,” <i>J Am Acad Dermatol</i>, 2010, 62(4):582-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/20133013/pubmed" id="20133013" target="_blank">20133013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25791801">
<a name="25791801"></a>Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. <i>J Am Acad Dermatol</i>. 2015;72(6):1047-1053. doi:10.1016/j.jaad.2015.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/25791801/pubmed" id="25791801" target="_blank">25791801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30392755">
<a name="30392755"></a>Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. <i>J Am Acad Dermatol</i>. 2019;80(1):208-250. doi:10.1016/j.jaad.2018.08.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/30392755/pubmed" id="30392755" target="_blank">30392755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28261899">
<a name="28261899"></a>Tandon S, Singh J, Sinha S, Sharma DP. Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod. <i>Dermatol Ther</i>. 2017;30(3). doi:10.1111/dth.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/28261899/pubmed" id="28261899" target="_blank">28261899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12453012">
<a name="12453012"></a>Tyring S, Conant M, Marini M, et al, “Imiquimod; An International Update on Therapeutic Uses in Dermatology,” <i>Int J Dermatol</i>, 2002, 41(11):810-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/12453012/pubmed" id="12453012" target="_blank">12453012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Accessed June 15, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32632956">
<a name="32632956"></a>Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. <i>Cochrane Database Syst Rev</i>. 2020;7(7):CD008946. doi:10.1002/14651858.CD008946.pub3<b></b>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/32632956/pubmed" id="32632956" target="_blank">32632956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imiquimod-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.2">
<a name="Bausch.2"></a>Vyloma (imiquimod) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.3">
<a name="Bausch.3"></a>Zyclara (imiquimod) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.4">
<a name="Bausch.4"></a>Zyclara (imiquimod) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; October 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8638 Version 286.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
